Pharma

Your Article Summary

See Latest Articles

Amgen Provides Update on Status of Prolia Biologics License Application Submitted to the U.S. Food and Drug Administration
Amgen, 10/20/09

Amgen Inc. announced that the U.S. Food and Drug Administration has issued a Complete Response Letter for the Biologic License Applications for Prolia in the treatment and prevention of postmenopausal osteoporosis.

Today in Drug/Product Approvals...keeping you current

Receive free subspecialty "5-minute updates" via email

Multaq Approved in the European Union for Patients with Atrial Fibrillation
Sanofi-aventis, 12/01/09

FDA drug approval intervals from 1997 to 2006: analysis and comparison during information technology implementation
International Journal of Electronic Healthcare , 12/01/09

FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS
BioMarin, 12/01/09

 See all of Drug/Product Approvals